SUPPLEMENTARY MATERIALS

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea

Ji Yeon Lee[1], Seon Hee Bu[2], EunHyang Song[3], Seongcheol Cho[4], Sungbong Yu[5], Jungok Kim[6], Sungmin Kym[6], Kwang Won Seo[7], Ki Tae Kwon[8], Jin Yong Kim[9], Sunghyun Kim[10], Keumyoung Ahn[10], Nahyun Jung[10], Yeonmi Lee[10], Yoobin Jung[10], Chankyoung Hwang[10], Sang Won Park[11,*]

[1]Keimyung University Daegu Dongsan Hospital, Daegu, Republic of Korea
[2]Seoul Metropolitan City Bukbu Hospital, Seoul, Republic of Korea
[3]Seoul Metropolitan City Seobuk Hospital, Seoul, Republic of Korea
[4]Seoul Red Cross Hospital, Seoul, Republic of Korea
[5]Bagae General Hospital, Pyeongtaek, Republic of Korea
[6]Chungnam National University Sejong Hospital, Sejong, Republic of Korea
[7]Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
[8]School of Medicine, Kyungpook National University, Daegu, Republic of Korea
[9]Incheon Medical Centre, Incheon, Republic of Korea
[10]Celltrion, Inc., Incheon, Republic of Korea
[11]Seoul National University Boramae Medical Centre, Seoul, Republic of Korea

[*] Corresponding author at hswon1@snu.ac.kr

Table S1 Study centres

Study centre name	City
Bagae General Hospital	Pyeongtaek
Chung-Ang University Healthcare System Hyundae Hospital	Namyangju
Chungnam National University Sejong Hospital	Sejong
Daegu Medical Center	Daegu
Gangwon-do Wonju Medical Center	Wonju
Incheon Medical Center	Incheon
Jeju National University Hospital	Jeju
Keimyung University Daegu Dongsan Hospital	Daegu
Konyang University Hospital	Daejeon
Kyungpook National University Chilgok Hospital	Daegu
Mokpo City Medical Center	Mokpo
Pusan National University Hospital	Pusan
Seoul Metropolitan City Bukbu Hospital	Seoul
Seoul Metropolitan City Seobuk Hospital	Seoul
Seoul National University Boramae Medical Center	Seoul
Seoul Red Cross Hospital	Seoul
Ulsan University Hospital	Ulsan

Table S2 Regdanvimab administration (safety analysis set)

	Regdanvimab (*N* = 3,036)
Total administered dose (mg), median (range)	2663.0 (264–6480)
Total administered dose (mg/kg), median (range)	40.0 (4.8–56.7)
Permanent discontinuation of regdanvimab, *n* (%)[a]	9 (0.3)
Reason for permanent discontinuation of regdanvimab[b]	
Adverse event	9 (100)
Administrated dose in patients with permanent discontinuation of regdanvimab (mg/kg), median (range)	24.0 (4.8–39.8)

[a]Percentages for 'Permanent discontinuation of regdanvimab' were calculated using the number of patients in the safety analysis set as the denominator
[b]Percentage for 'Reason for permanent discontinuation of regdanvimab' was calculated using the number of patients who permanently discontinued regdanvimab as the denominator

Table S3 Time from symptom onset to administration of oxygen therapy

		Baseline severity of COVID-19		
	Total (*N* = 3036)	**Mild (*n* = 1030)**	**Moderate (*n* = 2006)**	***P* value**
Patients requiring oxygen therapy after regdanvimab infusion up to day 28, n (%)	282 (9.3)	56 (5.4)	226 (11.3)	< 0.001
Days from symptom onset to oxygen therapy, median (range)	7 (1–21)	7.5 (1–21)	6 (1–14)	0.068
Days from symptom onset to regdanvimab infusion, median (range)	4 (0–7)	2.5 (0–7)	4 (0–7)	< 0.001
Days from regdanvimab infusion to oxygen therapy, median (range)	2 (0–20)	4 (0–20)	1.5 (0–10)	< 0.001
Symptom onset to regdanvimab infusion ≤ 3 days, n (%)[a]	115/282 (40.8)	36/56 (64.3)	79/226 (35.0)	< 0.001
Symptom onset to regdanvimab infusion > 3 days, n (%)[a]	167/282 (59.2)	20/56 (35.7)	147/226 (65.0)	

Includes only cases where supplementary oxygen therapy was applied for ≥ 24 h due to worsening symptoms of COVID-19 (SpO_2 ≤ 94% in room air) after regdanvimab infusion up to day 28 per protocol

[a]Percentages were calculated using the number of patients who received oxygen therapy for each severity group as the denominator

SpO_2 oxygen saturation